Clinical Study

Lipid profile changes during different hormone therapy regimens in postmenopausal women

  • Hikmet Hassa
  • Basar Tekin
  • Tufan Öge
  • Hüseyin Mete Tanir
  • Salih Kahraman
  • Tanser Senses
  • Cengiz Bal

Received Date: 13.10.2006 Accepted Date: 08.12.2006 J Turk Ger Gynecol Assoc 2007;8(1):17-21

OBJECTIVE

To compare the effects of hormone therapy on serum lipids in postmenopausal women.

Study Design

A retrospective study in 173 healthy postmenopausal women enrolled for this study. Participants had received 2 mg 17 β estradiol (E2) and 1 mg norethisterone acetate (E2/NETA) (n=21), 0.625 mg conjugated equine estrogen (CEE) and 2.5 mg medroxyprogesterone acetate (MPA) (n=38), 0.625 mg conjugated equine estrogen and 5 mg medroxyprogesterone acetate (n=39) and 2.5 mg tibolone (n=75). From the medical records, fasting serum lipid samples were evaluated before and after 6 months of treatment.

RESULTS

Total cholesterol decreased significantly only in E2/NETA group (p<0.05). Mean levels of LDL decreased significantly in E2/NETA (p<0.05) and CEE/2.5 mg MPA (p<0.05). There was a significant increase of HDL within the CEE/5 mg MPA group (p<0.01), whereas in the other groups increase of HDL was not found to be significant. Triglycerides decreased in all groups although the difference was not significant. When percent lipid profile changes among four groups were compared, only percent changes in LDL was significant between E2/NETA and tibolone group.

CONCLUSION

Different hormone therapy regimes have different effect on lipid profile and none of them was seem to be perfect. While many other factors are important for the cardiovascular system, changing of lipid profile may have an important role; so that when prescribing hormone therapy, lipid profile should be evaluated and monitorized thereafter.

Keywords: Hormone therapy, lipid profile, medroxyprogesterone acetate, norethisterone acetate, tibolone